Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition

Lyu, Q., Lin, A., Cao, M., Xu, X., Luo, P., & Zhang, J. (2020) · Cancer Control · doi:10.1177/1073274820976665 · Cited by 42

Novel Immune Infiltrating Cell Signature Based on Cell Pair Algorithm Is a Prognostic Marker in Cancer

Zhang, H., Wang, Z., Dai, Z., Wu, W., Cao, H., Li, S., Zhang, N., & Cheng, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.694490 · Cited by 40

Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures

Hossain, S. M., Gimenez, G., Stockwell, P. A., Tsai, P., Print, C. G., Ryś, J., Cybulska-Stopa, B., Ratajska, M., Harazin-Lechowska, A., Almomani, S. N., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.955063 · Cited by 40

Organoid technology and applications in cancer immunotherapy and precision medicine

Homicskó, K. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.05.002 · Cited by 40

A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival

Turan, T., Kongpachith, S., Halliwill, K. D., Roelands, J. P., Hendrickx, W., Marincola, F. M., Hudson, T. J., Jacob, H. J., Bedognetti, D., Samayoa, J. A., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01145-4 · Cited by 40

Tumour grade significantly correlates with total dysfunction of tumour tissue-infiltrating lymphocytes in renal cell carcinoma

Kawashima, A., Kanazawa, T., Kidani, Y., Yoshida, T., Hirata, M., Nishida, K., Nojima, S., Yamamoto, Y., Kato, T., Hatano, K., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-63060-1 · Cited by 41

Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study

Shen, L., Qi, H., Chen, S., Cao, F., Xie, L., Wu, Y., Ma, W., Song, Z., Yuan, H., Zhang, T., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02566-z · Cited by 40

Distinctive genomic characteristics in POLE/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitor

He, J.-J., Ouyang, W., Zhao, W., Shao, L., Li, B., Liu, B., Wang, D., Han‐Zhang, H., Zhang, Z., Shao, L., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-7553 · Cited by 39

Molecular dissection of CRC primary tumors and their matched liver metastases reveals critical role of immune microenvironment, EMT and angiogenesis in cancer metastasis

Liu, J., Cho, Y. B., Hong, H. K., Wu, S., Ebert, P. J., Bray, S. M., Wong, S. S., Ting, J. C., Calley, J. N., Whittington, C. F., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-67842-5 · Cited by 38

Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma

Liu, J., Geng, R., Yang, S., Shao, F., Zhong, Z., Yang, M., Ni, S., Cai, L., & Bai, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.788431 · Cited by 39

Unlocking the Secrets of Extracellular Vesicles: Orchestrating Tumor Microenvironment Dynamics in Metastasis, Drug Resistance, and Immune Evasion

Mir, R., Baba, S. K., Elfaki, I., Algehainy, N. A., Alanazi, M. A., Altemani, F. H., Tayeb, F. J., Barnawi, J., Husain, E., Bedaiwi, R. I., et al. (2024) · Journal of Cancer · doi:10.7150/jca.98426 · Cited by 39

Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression

Lin, Z., Gu, J., Cui, X., Huang, L., Li, S., Feng, J., Liu, B., & Zhou, Y. (2018) · Journal of Cancer · doi:10.7150/jca.26444 · Cited by 37

An Emerging Regulatory Role for the Tumor Microenvironment in the DNA Damage Response to Double-Strand Breaks

Lama-Sherpa, T. D., & Shevde, L. A. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0665 · Cited by 37

Analyzing the characteristics of immune cell infiltration in lung adenocarcinoma via bioinformatics to predict the effect of immunotherapy

Liao, Y., He, D., & Wen, F. (2021) · Immunogenetics · doi:10.1007/s00251-021-01223-8 · Cited by 36

Engineering ROS‐Responsive Bioscaffolds for Disrupting Myeloid Cell‐Driven Immunosuppressive Niche to Enhance PD‐L1 Blockade‐Based Postablative Immunotherapy

Li, S., Zhu, C., Zhou, X., Chen, L., Bo, X., Shen, Y., Guan, X., Han, X., Shan, D., Sun, L., et al. (2022) · Advanced Science · doi:10.1002/advs.202104619 · Cited by 38

ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance

Mellone, M., Piotrowska, K., Venturi, G., James, L., Bzura, A., Lopez, M. A., James, S., Wang, C., Ellis, M. J., Hanley, C. J., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0435 · Cited by 36

Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha

Sahu, A. D., Wang, X., Munson, P. B., Klomp, J. P. G., Wang, X., Gu, S. S., Qian, G., Nicol, P., Zeng, Z., Wang, C., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0244 · Cited by 35

Immune Cell Types and Secreted Factors Contributing to Inflammation-to-Cancer Transition and Immune Therapy Response

Chen, X., Chi, X., Hong, S., Xia, X., Cao, Y., McDermott, J., Mu, Y., & Han, J. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.080 · Cited by 36

Investigating Mechanisms of Response or Resistance to Immune Checkpoint Inhibitors by Analyzing Cell-Cell Communications in Tumors Before and After Programmed Cell Death-1 (PD-1) Targeted Therapy: An Integrative Analysis Using Single-cell RNA and Bulk-RNA Sequencing Data

Jiang, Y., Wang, Z., Zhong, M., Shen, L., Han, X., Zou, X., Liu, X.-Y., Deng, Y.-N., Yang, Y., Chen, G., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1908010 · Cited by 37

Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial

Noviello, T., Giacomo, A. M. D., Caruso, F. P., Covre, A., Mortarini, R., Scala, G., Costa, M. C., Coral, S., Fridman, W. H., Sautès‐Fridman, C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40994-4 · Cited by 44

Predicting patient outcomes after treatment with immune checkpoint blockade: A review of biomarkers derived from diverse data modalities

Liu, Y., Altreuter, J., Bodapati, S., Cristea, S., Wong, C. J., Wu, C. J., & Michor, F. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100444 · Cited by 39

neoepiscope improves neoepitope prediction with multivariant phasing

Wood, M. A., Nguyen, A., Struck, A. J., Ellrott, K., Nellore, A., & Thompson, R. F. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz653 · Cited by 35

Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications

Ryan, M. J., & Bose, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01287 · Cited by 40

Silencing of STAT3 via Peptidomimetic LNP-Mediated Systemic Delivery of RNAi Downregulates PD-L1 and Inhibits Melanoma Growth

Ehexige, E., Bao, M., Bazarjav, P., et al. (2020) · Biomolecules · doi:10.3390/biom10020285 · Cited by 35

Development and Validation of a Hypoxia-Related Signature for Predicting Survival Outcomes in Patients With Bladder Cancer

Zhang, F., Wang, X., Bai, Y., Hu, H., Yang, Y., Wang, J., Tang, Y., Ma, H., Feng, D., Li, D., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.670384 · Cited by 34

Grainyhead-like-2 confers NK-sensitivity through interactions with epigenetic modifiers

MacFawn, I., Wilson, H. E., Selth, L. A., Leighton, I. A., Serebriiskii, I. G., Bleackley, R. C., Elzamzamy, O. M., Farris, J. C., Pifer, P. M., Richer, J. K., et al. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.11.006 · Cited by 29

Antibody–drug conjugates for lung cancer in the era of personalized oncology

Ricciuti, B., Lamberti, G., Andrini, E., Genova, C., Giglio, A. D., Bianconi, V., Sahebkar, A., Chiari, R., & Pirro, M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.024 · Cited by 35

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors

Chen, Y., Li, Y., Guan, Y., Huang, Y., Lin, J., Chen, L., Li, J., Chen, G., Pan, L. K., Xia, X., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12739 · Cited by 36

Testicular Degeneration and Infertility following Arbovirus Infection

Puggioni, G., Pintus, D., Melzi, E., et al. (2018) · Journal of Virology · doi:10.1128/jvi.01131-18 · Cited by 33

Molecular Targeting of the Fibroblast Growth Factor Receptor Pathway across Various Cancers

Shan, K., Dalal, S., Dar, N. N. T., McLish, O., Salzberg, M., & Pico, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020849 · Cited by 29

Exosomal PD-L1 in cancer and other fields: recent advances and perspectives

Lu, M., & Yang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1395332 · Cited by 35

Strategy to targeting the immune resistance and novel therapy in colorectal cancer

Wang, G., Wang, J., Guan, R., Sun, Y., Shi, F., Zhang, J., Li, Z., Gao, J., & Fu, X. (2018) · Cancer Medicine · doi:10.1002/cam4.1386 · Cited by 33

High G2 and S‐phase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis

Xu, T., Ma, M., Chi, Z., et al. (2018) · Cancer Science · doi:10.1111/cas.13607 · Cited by 31

Preoperative Radiomics Approach to Evaluating Tumor‐Infiltrating CD8+ T Cells in Patients With Pancreatic Ductal Adenocarcinoma Using Noncontrast Magnetic Resonance Imaging

Bian, Y., Liu, C., Li, Q., Meng, Y., Liu, F., Zhang, H., Fang, X., Li, J., Yu, J.-Y., Feng, X.-C., et al. (2021) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.27871 · Cited by 24

SP140 inhibits STAT1 signaling, induces IFN-γ in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response

Tanagala, K. K. K., Morin‐Baxter, J., Carvajal, R. D., Cheema, M., Dubey, S., Nakagawa, H., Yoon, A. J., Cheng, Y. L., Taylor, A. M., Nickerson, J. A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005088 · Cited by 31

Management of V600E and V600K BRAF-Mutant Melanoma

Haugh, A. M., & Johnson, D. B. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0680-z · Cited by 30

Clonal tracing reveals diverse patterns of response to immune checkpoint blockade

Gu, S. S., Wang, X., Hu, X. S., Jiang, P., Li, Z., Traugh, N. C., Bu, X., Tang, Q., Wang, C., Zeng, Z., et al. (2020) · Genome biology · doi:10.1186/s13059-020-02166-1 · Cited by 29

Expression Profile Analysis of m6A RNA Methylation Regulators Indicates They Are Immune Signature Associated and Can Predict Survival in Kidney Renal Cell Carcinoma

Fang, J., Hu, M., Sun, Y., Zhou, S., & Li, H. (2020) · DNA and Cell Biology · doi:10.1089/dna.2020.5767 · Cited by 29

IL-1α Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma

Singh, S., Xiao, Z., Bavisi, K., Roszik, J., Melendez, B., Wang, Z., Cantwell, M. J., Davis, R. E., Lizee, G. A., Hwu, P., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2000523 · Cited by 30

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study

Hamid, O., Hassel, J. C., Shoushtari, A. N., Meier, F. E., Bauer, T. M., Salama, A. K. S., Kirkwood, J. M., Ascierto, P. A., Lorigan, P. C., Mauch, C., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006747 · Cited by 33

A Predictive Network‐Based Immune Checkpoint Blockade Immunotherapeutic Signature Optimizing Patient Selection and Treatment Strategies

Zhang, N., Yang, M., Yang, J., Zhang, C., & Guo, A. (2024) · Small Methods · doi:10.1002/smtd.202301685 · Cited by 27

Capturing Functional Long Non-Coding RNAs Through Integrating Large-Scale Causal Relations from Gene Perturbation Experiments

Xu, J., Shi, A., Long, Z., Xu, L., Liao, G., Deng, C., Yan, M., Xie, A., Luo, T., Huang, J. H., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.050 · Cited by 26

Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma

Yu, J., Wu, X., Song, J., Zhao, Y., Li, H., Luo, M., & Liu, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.928226 · Cited by 27

Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies

Dovey, Z. S., Nair, S. S., Chakravarty, D., & Tewari, A. K. (2021) · Cancer Reports · doi:10.1002/cnr2.1340 · Cited by 29

Identification of LIPH as an unfavorable biomarkers correlated with immune suppression or evasion in pancreatic cancer based on RNA-seq

Zhuang, H., Chen, X., Wang, Y., Huang, S., Chen, B., Zhang, C., & Hou, B. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03019-x · Cited by 26

A score of DNA damage repair pathway with the predictive ability for chemotherapy and immunotherapy is strongly associated with immune signaling pathway in pan-cancer

Ding, K., He, Y., Wei, J., Fu, S., Wang, J., Chen, Z., Zhang, H., Qu, Y., Liang, K., Gong, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.943090 · Cited by 23

Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signaling

Shen, H., Huang, F., Zhang, X., Ojo, O. A., Li, Y., Trummell, H. Q., Anderson, J. C., Fiveash, J. B., Bredel, M., Yang, E. S.-H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32754-7 · Cited by 27

B3GNT3 overexpression promotes tumor progression and inhibits infiltration of CD8+ T cells in pancreatic cancer

Zhuang, H., Zhou, Z., Zhang, Z., Chen, X., Ma, Z., Huang, S., Gong, Y., Zhang, C., & Hou, B. (2020) · Aging · doi:10.18632/aging.202255 · Cited by 25

A web platform for the network analysis of high-throughput data in melanoma and its use to investigate mechanisms of resistance to anti-PD1 immunotherapy

Dreyer, F. S., Cantone, M., Eberhardt, M., Jaitly, T., Walter, L. M., Wittmann, J., Gupta, S. K., Khan, F. M., Wolkenhauer, O., Pützer, B. M., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.01.020 · Cited by 23

S100A9+CD14+ monocytes contribute to anti-PD-1 immunotherapy resistance in advanced hepatocellular carcinoma by attenuating T cell-mediated antitumor function

Tu, X., Chen, L., Zheng, Y., Mu, C., Zhang, Z., Wang, F., Ren, Y., Duan, Y., Zhang, H., Tong, Z., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02985-1 · Cited by 23

INHBA promotes tumor growth and induces resistance to PD-L1 blockade by suppressing IFN-γ signaling

Li, F., Gu, L., Tong, Y.-L., Chen, R.-Q., Chen, S., Yu, X., Liu, N., Lu, J.-L., Si, Y., Sun, J., et al. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01381-x · Cited by 27

Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors

Fenton, S. E., Sosman, J. A., & Chandra, S. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.28 · Cited by 28

Glutamine Metabolism Scoring Predicts Prognosis and Therapeutic Resistance in Hepatocellular Carcinoma

Ying, L., Cheng, M., Lü, Y., Tao, Q., Chen, X., Shen, B., Xiong, F., Hu, Z., Wang, D., & Li, X. (2021) · Pathology & Oncology Research · doi:10.3389/pore.2021.1610075 · Cited by 25

CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma

Jiang, Y., Ji, Q., Long, X., Wang, P., Tu, Z., Zhang, X., Xingen, Z., Huang, K., & Li, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.810832 · Cited by 23

CD16 CAR-T cells enhance antitumor activity of CpG ODN-loaded nanoparticle-adjuvanted tumor antigen-derived vaccinevia ADCC approach

Zhang, X., Hu, Q., He, X., Cui, X., Liang, Z., Wang, L., Deng, X., Zhang, Z., Wang, S., & Han, X. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01900-8 · Cited by 23

Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma

Ruff, S. M., Manne, A., Cloyd, J. M., Dillhoff, M., Ejaz, A. M., & Pawlik, T. M. (2023) · Current Oncology · doi:10.3390/curroncol30060439 · Cited by 23

The tertiary lymphoid structure-related signature identified PTGDS in regulating PD-L1 and promoting the proliferation and migration of glioblastoma

Wu, W., Li, H., Wang, Z., Dai, Z., Liang, X., Luo, P., Liu, K., Zhang, H., Zhang, N., Li, S., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23915 · Cited by 24

Applying an innovative biodegradable self-assembly nanomicelles to deliver α-mangostin for improving anti-melanoma activity

Yang, S., Gao, X., He, Y., Hu, Y., Xu, B., Cheng, Z., Xiang, M., & Xie, Y. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1323-9 · Cited by 23

Transcriptome analysis reveals GPNMB as a potential therapeutic target for gastric cancer

Ren, F., Zhao, Q., Liu, B., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29177 · Cited by 23

The prognostic value of tumor mutational burden and immune cell infiltration in esophageal cancer patients with or without radiotherapy

Yuan, C., Xiang, L., Cao, K., et al. (2020) · Aging · doi:10.18632/aging.102917 · Cited by 23

Machine learning-based investigation of regulated cell death for predicting prognosis and immunotherapy response in glioma patients

Zhang, W., Dang, R., Liu, H., Dai, L., Liu, H., Adegboro, A. A., Zhang, Y., Li, W., Peng, K., Hong, J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-54643-3 · Cited by 25

Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a Mycoplasma fermentans Lipopeptide

Takeda, Y., Azuma, M., Funami, K., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00496 · Cited by 22

Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy–Resistant Early Breast Cancers

Gazińska, P., Milton, C. K., Iacovacci, J., Ward, J. A., Buus, R., Alaguthurai, T., Graham, R. A., Akarca, A. U., Lips, E. H., Naidoo, K., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0543 · Cited by 23

Identifying biomarkers associated with immunotherapy response in melanoma by multi-omics analysis

He, Y., & Wang, X. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107591 · Cited by 23

Magnolol induces cell death through PI3K/Akt‐mediated epigenetic modifications boosting treatment of BRAF‐ and NRAS‐mutant melanoma

Emran, A. A., Chowdary, B. R. C., Ahmed, F., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.1978 · Cited by 22

A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance

Huang, Q., Lei, Y., Li, X., Guo, F., & Liu, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.580140 · Cited by 22

Genetic and immune characteristics of sentinel lymph node metastases and multiple lymph node metastases compared to their matched primary breast tumours

Chen, B., Zhang, G., Lai, J., Xiao, W., Li, X., Li, C., Mok, H., Li, K., Wang, Y., Cao, L., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103542 · Cited by 21

Inflammatory response signature score model for predicting immunotherapy response and pan-cancer prognosis

Chen, S., Huang, M., Zhang, L., Huang, Q., Wang, Y., & Yang, L. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.12.001 · Cited by 22

Characteristics of Oxidative Phosphorylation-Related Subtypes and Construction of a Prognostic Signature in Ovarian Cancer

Lu, J., Zhen, S., & Li, X. (2024) · Current Gene Therapy · doi:10.2174/0115665232323373240905104033 · Cited by 20

TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy

Eckardt, J., Schroeder, C., Martus, P., Armeanu–Ebinger, S., Kelemen, O., Gschwind, A., Bonzheim, I., Eigentler, T., Amaral, T. M. S., Ossowski, S., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-03939-w · Cited by 23

Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene Alterations

Khushman, M. M., Toboni, M. D., Xiu, J., Manne, U., Farrell, A. P., Lou, E., Shields, A. F., Philip, P. A., Salem, M. E., Abraham, J. P., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3004 · Cited by 20

Case report: reinitiating pembrolizumab treatment after small bowel perforation

Beck, T. N., Kudinov, A. E., Dulaimi, E., & Boumber, Y. (2019) · BMC Cancer · doi:10.1186/s12885-019-5577-5 · Cited by 20

Gene expression profiling identified TP53MutPIK3CAWild as a potential biomarker for patients with triple-negative breast cancer treated with immune checkpoint inhibitors

Cheng, J.-N., Ding, X.-F., Xu, S.-X., Zhu, B., & Jia, Q. (2020) · Oncology Letters · doi:10.3892/ol.2020.11381 · Cited by 14

Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype

Jézéquel, P., Lasla, H., Gouraud, W., Basseville, A., Michel, B., Frenel, J., Juin, P. P., Azzouz, F. B., & Campone, M. (2024) · Breast Cancer · doi:10.1007/s12282-024-01597-z · Cited by 20

Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives

Kwok, M., Agathanggelou, A., Davies, N., & Stanković, T. (2021) · Cancers · doi:10.3390/cancers13184681 · Cited by 20

Transcriptional determinants of cancer immunotherapy response and resistance

Gupta, R., Mehta, A., & Wajapeyee, N. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.01.008 · Cited by 23

Pyroptosis-related gene expression patterns and corresponding tumor microenvironment infiltration characterization in ovarian cancer

Liu, J., Chen, C., Geng, R., Shao, F., Yang, S., Zhong, Z., Ni, S., & Bai, J. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.09.037 · Cited by 20

Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors

Abenavoli, L., Montori, M., Svegliati‐Baroni, G., Argenziano, M. E., Giorgi, F., Scarlata, G. G. M., Ponziani, F. R., & Scarpellini, E. (2023) · Medicina · doi:10.3390/medicina59081427 · Cited by 21

PTPRC functions as a prognosis biomarker in the tumor microenvironment of cutaneous melanoma

Li, X., Yue, Z., Wang, D., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-46794-6 · Cited by 19

Acquired Resistance to Immune Checkpoint Blockade Therapies

Zhao, X., Wangmo, D., Robertson, M. J., & Subramanian, S. (2020) · Cancers · doi:10.3390/cancers12051161 · Cited by 19

Transcriptional Activity and Stability of CD39+CD103+CD8+ T Cells in Human High-Grade Endometrial Cancer

Workel, H. H., van Rooij, N., Plat, A., Spierings, D. C. J., Fehrmann, R. S. N., Nijman, H. W., & de Bruyn, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113770 · Cited by 20

A TCF4/BRD4-dependent regulatory network confers cross-resistance to targeted and immune checkpoint therapy in melanomaPreprint

Poźniak, J., Pedri, D., Landeloos, E., Herck, Y. V., Antoranz, A., Karras, P., Nowosad, A., Makhzami, S., Bervoets, G., Dewaele, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.11.502598 · Cited by 21

Advanced Melanoma

Haugh, A. M., Salama, A. K. S., & Johnson, D. B. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.09.005 · Cited by 20

Loss of LRRC33-Dependent TGFβ1 Activation Enhances Antitumor Immunity and Checkpoint Blockade Therapy

Jiang, A., Qin, Y., & Springer, T. A. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0593 · Cited by 18

Artificial intelligence learning landscape of triple-negative breast cancer uncovers new opportunities for enhancing outcomes and immunotherapy responses

Li, S., Zhang, N., Zhang, H., Zhou, R., Li, Z., Yang, X. Y., Wu, W., Li, H., Luo, P., Wang, Z., et al. (2023) · Journal Of Big Data · doi:10.1186/s40537-023-00809-1 · Cited by 18

A Large-Scale Meta-Analysis Reveals Positive Feedback between Macrophages and T Cells That Sensitizes Tumors to Immunotherapy

Yang, J., Liu, Q., & Shyr, Y. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-2006 · Cited by 18

Immunoreactive Microenvironment Modulator GBP5 Suppresses Ovarian Cancer Progression by Inducing Canonical Pyroptosis

Zou, C., Shen, J., Xu, F., Ye, Y., Wu, Y., & Xu, S. (2024) · Journal of Cancer · doi:10.7150/jca.94616 · Cited by 20

Functional Genomic Complexity Defines Intratumor Heterogeneity and Tumor Aggressiveness in Liver Cancer

Kwon, S. M., Budhu, A., Woo, H. G., Chaisaingmongkol, J., Dang, H. T., Forgues, M., Harris, C. C., Zhang, G., Auslander, N., Ruppin, E., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-52578-8 · Cited by 18

Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors

Schlauch, D., Fu, X., Jones, S. F., Burris, H. A., Spigel, D. R., Reeves, J. A., & McKenzie, A. J. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00008 · Cited by 18

Papillary Thyroid Carcinoma Variants are Characterized by Co-dysregulation of Immune and Cancer Associated Genes

Chakladar, J., Li, W.-T., Bouvet, M., Chang, E. Y., Wang-Rodriguez, J., & Ongkeko, W. (2019) · Cancers · doi:10.3390/cancers11081179 · Cited by 13

A programmed cell death-related model based on machine learning for predicting prognosis and immunotherapy responses in patients with lung adenocarcinoma

Zhang, Y., Wang, Y., Chen, J., Xia, Y., & Huang, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1183230 · Cited by 18

Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives

Bobrowicz, M., Zagożdżon, R., Domagała, J., Vasconcelos‐Berg, R., Guenova, E., & Winiarska, M. (2019) · Cancers · doi:10.3390/cancers11101420 · Cited by 17

Is tumor mutational burden predictive of response to immunotherapy?Preprint

Gurjao, C., Tsukrov, D. I., Imakaev, M., Luquette, L. J., & Mirny, L. A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.03.260265 · Cited by 17

Towards designing improved cancer immunotherapy targets with a peptide-MHC-I presentation model, HLApollo

Thrift, W. J., Lounsbury, N., Broadwell, Q., Heidersbach, A. J., Freund, E. C., Abdolazimi, Y., Phung, Q. T., Chen, J., Capietto, A.-H., Tong, A.-J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54887-7 · Cited by 20

First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma

Turajlic, S., Gore, M. E., & Larkin, J. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy020 · Cited by 16

Comprehensive Characterization of Immune Landscape Based on Epithelial-Mesenchymal Transition Signature in OSCC: Implication for Prognosis and Immunotherapy

Zhang, S.-Y., Ren, X., Wang, C., Chen, X., Cao, R., Liu, Q., Pan, X., Zhou, J., Zhang, W., Tang, X.-R., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.587862 · Cited by 18

Identification of an Autophagy-Related lncRNA Prognostic Signature and Related Tumor Immunity Research in Lung Adenocarcinoma

Chen, H., Hu, Z., Sang, M., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.767694 · Cited by 16

Exploring the Complex and Multifaceted Interplay between Melanoma Cells and the Tumor Microenvironment

Kuras, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814403 · Cited by 18

Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2

Novoyatleva, T., Rai, N., Kojonazarov, B. K., Veeroju, S., Batalla, I. B., Caruso, P. L., Shihan, M., Presser, N., Götz, E., Lepper, C., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02531-1 · Cited by 17

Turning Fluvastatin into a supramolecular immuno-sensitizer towards augmented tumor immunotherapy

Ma, F., Liu, T., Yang, W., You, W., He, W., Yan, J., & Liu, W. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.135310 · Cited by 15

The GENCODE exome: sequencing the complete human exome

Coffey, A. J., Kokocinski, F., Calafato, M., Scott, C., Palta, P., Drury, E., Joyce, C. J., LeProust, E. M., Harrow, J., Hunt, S. E., et al. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.28 · Cited by 64

The current landscape of clinical exome and genome reanalysis in the U.S.

Frees, M., Carter, J. N., Wheeler, M. T., & Reuter, C. M. (2024) · Journal of Genetic Counseling · doi:10.1002/jgc4.1968 · Cited by 5

Clinical Exome Performance for Reporting Secondary Genetic Findings

Park, J. Y., Clark, P., Londin, E. R., Sponziello, M., Kricka, L. J., & Fortina, P. M. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.231456 · Cited by 37

Exome Sequencing in Mendelian Disorders

Lee, J. (2010) · Journal of genetic medicine · doi:10.5734/jgm.2010.7.2.119 · Cited by 1

Diagnostic Exome Sequencing — Are We There Yet?

Mefford, H. C. (2012) · New England Journal of Medicine · doi:10.1056/nejme1211659 · Cited by 24